Importantly, the human IgM promotes myelin repair in human in MS by 5 weeks following treatment with a single, very low dose (500 ng) injection [233] and with an accompanying decreased lesion load detectable by MRI [234]. The gene discussed is CD40LG; the disease is myeloid sarcoma.